- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00653003
Bioavailability Study of Leflunomide Tablets Under Fed Conditions
To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will meet all of the following criteria within 30 days prior to first drug administration(except inclusion #8)
- Healthy, surgically sterile (hysterectomy, bilateral oophorectomy) or postmenopausal (for al least 1 year)female subjects, 18 to 65 years of age(inclusive)
- Indicate non-child bearing status by one of the following criteria:
Indication of successful hysterectomy. No spontaneous menses for al least 1 year, must have luteinizing hormone (LH) and follicle stimulating hormone(FSH) levels within postmenopausal range.
Indication of successful bilateral oophorectomy.
- Body weight within 20% of the appropriate weight for the subject's height and frame (as published in the 1983 Metropolitan Life Insurance Company Scale, Statistical Bureau)
- Negative for:
HIV Hepatitis B surface antigen and Hepatitis C antibody Urine tests for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
Serum HCG consistent with pregnancy.
- No significant disease or clinically significant findings in a physical examination.
- No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram(ECG)
- Subjects who have received leflunomide within 4 months must have an A77-1726(Metabolite) level below 0.01ug/ml and no subsequent administration of leflunomide since that test. Note: The 30 day screening limit does not apply to this inclusion criterion.
- Be informed of the nature of the study and given written consent prior to receiving any study procedures.
Exclusion Criteria:
- Subject fulfilling any of the following criteria will be excluded from the study.
- Known history or presence of any clinically significant medical condition.
- Known or suspected carcinoma.
- Known history or presence of:
- Hypersensitivity or idiosyncratic reaction to leflunomide and/or any other drug substances with similar activity.
- Alcoholism within the last 12 months.
- Drug dependence and/ or substance abuse.
- On a special diet within 4 weeks prior to drug administration(e.g. liquid, protein, raw food diet).
- Participated in another clinical trail or received an investigational product 30 days prior to drug administration.
- Donated up to 250 ml of blood in the past 45 days OR donated from 250 ml to 500 ml in the past 45 days OR donated 501 ml or more of blood in the past 56 days (based on the Canadian Blood Services guideline for blood donation).
- Requirement of any medication (prescription and/ or over-the-counter) on a routine basis, with the exception of hormonal replacement therapy, nutritional supplements and/or occasional use of common analgesics.
- Difficulty fasting or consuming the standard meals.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Subjects received Kali formulated product under fed conditions
|
tablets, 20mg, single-dose
Other Names:
|
Active Comparator: B
Subjects received Aventis formulated products under fed conditions
|
Tablets, 20mg, single-dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate and Extend of Absorption
Time Frame: 24 Hours
|
24 Hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Xueyu Chen, Pharma Medica Research, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-704
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Determine Bioequivalence Under Fed Conditions
-
Par Pharmaceutical, Inc.PharmaKinetics Laboratories Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsUnited States
-
Par Pharmaceutical, Inc.Algorithme Pharma IncCompletedTo Determine the Bioequivalence Study Under FedCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
AET Laboratories Private LimitedCompleted
-
Par Pharmaceutical, Inc.AAI ClinicCompletedTo Determine Bioequivalence Under Fed Conditions
-
AET Laboratories Private LimitedCompleted
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.SFBC AnapharmCompletedTo Determine Bioequivalence Under Fed Conditions
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
Clinical Trials on Leflunomide
-
PfizerNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States, Canada
-
University Hospital, LimogesUnknownBullous PemphigoidFrance
-
Ashford and St. Peter's Hospitals NHS TrustCompleted
-
SanofiCompletedArthritis, RheumatoidRomania, Portugal, Czech Republic, Italy, Korea, Republic of
-
Changzheng-CinkateTerminatedViremia | ViruriaUnited States
-
University Hospital, Basel, SwitzerlandRecruiting
-
Assiut UniversityCompleted
-
The First Affiliated Hospital of Anhui University...Ministry of Science and Technology of the People´s Republic of ChinaCompleted
-
Tata Memorial CentreRecruitingMusculoskeletal Disease Other | GVHD, ChronicIndia